hydroxyurea has been researched along with Infarction, Middle Cerebral Artery in 5 studies
Infarction, Middle Cerebral Artery: NECROSIS occurring in the MIDDLE CEREBRAL ARTERY distribution system which brings blood to the entire lateral aspects of each CEREBRAL HEMISPHERE. Clinical signs include impaired cognition; APHASIA; AGRAPHIA; weak and numbness in the face and arms, contralaterally or bilaterally depending on the infarction.
| Excerpt | Relevance | Reference |
|---|---|---|
| " He was thought to have had an embolic stroke and was initially treated with warfarin." | 3.80 | Repeated episodes of ischemic stroke over a short period in a patient with essential thrombocythemia on anticoagulant therapy. ( Hirano, T; Isoda, K; Ito, K; Naganuma, M; Nishi, S, 2014) |
| "Default of therapy for polycythemia is associated with a profound risk of recurrent strokes requiring patient education and support to prevent the devastating consequence of this modifiable but rare cause of stroke." | 1.51 | Recurrent Stroke in a Ghanaian Patient With Polycythemia. ( Berchie, PO; Opare-Sem, OK; Ovbiagele, B; Sarfo, FS, 2019) |
| "Adult male Sprague-Dawley rats underwent middle cerebral artery occlusion (MCAO), then received treatment with zileuton or vehicle after the onset of ischemia." | 1.43 | 5-LOX Inhibitor Zileuton Reduces Inflammatory Reaction and Ischemic Brain Damage Through the Activation of PI3K/Akt Signaling Pathway. ( Chen, CM; Liang, RS; Shi, SS; Tu, XK; Wang, CH; Yang, WZ; Zhang, HB, 2016) |
| "Oral treatment of zileuton at 10 or 50 mg/kg significantly reduced cerebral water content and infarct volume." | 1.35 | 5-lipoxygenase inhibitor zileuton attenuates ischemic brain damage: involvement of matrix metalloproteinase 9. ( Chen, CM; Shi, SS; Tu, XK; Wang, CH; Yang, WZ, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Berchie, PO | 1 |
| Sarfo, FS | 1 |
| Opare-Sem, OK | 1 |
| Ovbiagele, B | 1 |
| Shi, SS | 3 |
| Yang, WZ | 3 |
| Tu, XK | 3 |
| Wang, CH | 3 |
| Chen, CM | 3 |
| Chen, Y | 1 |
| Zhang, HB | 1 |
| Liang, RS | 1 |
| Naganuma, M | 1 |
| Isoda, K | 1 |
| Nishi, S | 1 |
| Ito, K | 1 |
| Hirano, T | 1 |
5 other studies available for hydroxyurea and Infarction, Middle Cerebral Artery
| Article | Year |
|---|---|
Recurrent Stroke in a Ghanaian Patient With Polycythemia.
Topics: Aphasia, Broca; Aspirin; Clopidogrel; Ghana; Humans; Hydroxyurea; Infarction, Middle Cerebral Artery | 2019 |
5-Lipoxygenase inhibitor zileuton inhibits neuronal apoptosis following focal cerebral ischemia.
Topics: Animals; Apoptosis; Arachidonate 5-Lipoxygenase; Brain; Brain Injuries; Caspase 1; Caspase 3; Hydrox | 2013 |
5-LOX Inhibitor Zileuton Reduces Inflammatory Reaction and Ischemic Brain Damage Through the Activation of PI3K/Akt Signaling Pathway.
Topics: Animals; Arachidonate 5-Lipoxygenase; Brain; Brain Ischemia; Hydroxyurea; Infarction, Middle Cerebra | 2016 |
5-lipoxygenase inhibitor zileuton attenuates ischemic brain damage: involvement of matrix metalloproteinase 9.
Topics: Animals; Arachidonate 5-Lipoxygenase; Body Water; Brain; Brain Edema; Brain Ischemia; Dose-Response | 2009 |
Repeated episodes of ischemic stroke over a short period in a patient with essential thrombocythemia on anticoagulant therapy.
Topics: Aged; Anticoagulants; Aphasia; Brain Ischemia; Cerebral Angiography; Cilostazol; Diffusion Magnetic | 2014 |